In an interaction with The Statesman, Dr Rishabh Yadav, MBBS, MS (Medical Superintendent) at a private hospital in the ...

Winter smog may fade, but lung damage can linger. Doctors explain how PM2.5 affects lung health, children’s immunity, and ...

Patients with SARD-ILD-PPF who continued nintedanib for 12 months or longer had better outcomes than those who discontinued therapy.

Clarametyx today announced positive topline data from a Phase 1b/2a trial evaluating its novel antibody therapy, CMTX-101, in cystic fibrosis (CF).

Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025Received more than 2,800 unique patient prescriptions since launch in ...

A new meeting report was published in Volume 17, Issue 12 of Aging-US on December 23, 2025, titled "Cellular senescence meets ...

Systemic therapy for sarcoidosis is reserved for organ-threatening disease, and laryngeal involvement necessitates treatment ...

MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through ...

Reduced diffusing capacity of the lungs for carbon monoxide (DLco) reflects microvasculopathy in chronic thromboembolic ...

When inflammation in the body goes unchecked, it can cause fibrosis, or tissue scarring that may lead to organ dysfunction or ...

Patients who have comorbid COPD with heart failure and ischemic heart disease have increased health care resource use and higher mortality.

CSA Medical, Inc., a medical device company focused on interventional pulmonary therapies, today announced the submission of ...